For the companies, the reports show their respective strategies reported by the Albany Business Review continue to gain traction. That is a promising development considering they are among the largest employers in the Albany region.

There is some good news this morning for nearly 1,600 jobs at regional operations of Albany Molecular Research Inc. and Regeneron Pharmaceuticals Inc.

The two drug development companies reported strong gains during the second quarter of 2014, which ended June 30.

For the companies, the reports show their respective strategies reported by the Albany Business Review continue to gain traction. That is a promising development considering they are among the largest employers in the Albany region.

Here are some takeaways from this morning’s quarterly earnings reports:
Regeneron (Nasdaq: REGN) increased total revenue by 45 percent to $666 million, compared to $458 million in the year-ago period. The Tarrytown, New York-based company has about 2,500 employees total. That includes nearly 900 at its manufacturing plant in East Greenbush, just outside Albany

The company attributed some of its recent gains to strong sales of Eylea, its drug to treat macular degeneration, a top cause of blindness in older people. Investments from Sanofi, a French company that has partnered with Regeneron on developing new drugs, also prompted the continued success, the report shows.

“Regeneron continued to make progress across all aspects of our business, delivering continued growth and another strong quarter,” said Leonard Schleifer, president and chief executive officer of Regeneron.
During the second quarter, Regeneron reported net income of $93 million, or 92 cents per basic share. That’s compared to net income of $87 million, or 89 cents per basic share, the prior year

David Robinson